 we report on our third quarter 2019 financial results and discuss our plans for commercialization of cytisinicline. 
 we also discuss our ongoing regulatory discussions with the FDA and discuss our plans for the third phase of the clinical trials.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 